the aid library

LIST OPTIONS

Filter

6017

Download (635)

View PDF (719)

Venezuela´s humanitarian crisis. Severe Medical and Food Shortages, Inadequate and Repressive Government Response

Human Rights Watch (2016) C1

Download (509)

View PDF (417)

Direct and indirect effects of COVID-19 on maternal and child health in Bangladesh

M. M. Ahmmed; M. A. Babu; J. Ferdosy (2021) CC

Bangladesh has been going through incremental trend of GDP growth rates for a long time. The GDP is the key aspect to measure the economic growth of a country. But the current world wide pandemic due to the COVID-19 hardly affects the world’s economy as well as Bangladesh. The present... more

Download (353)

View PDF (477)

Country overview: Georgia

J.D. Javakhishvili; L. Sturua; I. Kirtadze; et al. European Monitoring Centre for Drugs and Drug Addiction (2015) C2

Download (475)

View PDF (445)

Saving Mothers, Giving Life. Maternal Mortality Endline Census in Selected Districts

Central Statistical Office (CSO) Zambia, Ministry of Health (MOH) Zambia, and ICF, et al. (2017) C1

Download (434)

View PDF (499)

Global vaccine safety blueprint 2.0 (GVSB2.0) 2021-2023

World Health Organization WHO (2022) C_WHO

Download (391)

View PDF (530)

South-East Asia Regional Action Plan on Programmatic Management of Latent Tuberculosis Infection

World Health Organization (WHO), Regional Office for South-East Asia (2020) C_WHO

External Link

The achievement of a storytelling about Chagas disease: how to talk about silence; how to visualise the invisible

Mas, F. National Library of Medicine (2022) CC

Mem Inst Oswaldo Cruz, Rio de Janeiro, Vol. 117: e220083chgsa, 2022 Two adjectives raise an issue for communicators working on Chagas disease (CD): “invisible and silent”. Two adjectives that can be ascribed to other neglected tropical diseases (NTD), but which are part of the essence of CD. Br... more

Download (542)

View PDF (749)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

Download (345)

View PDF (409)

Checklist for assessing quality of healthcare - Hospitals

Kenya Ministry of Health (2021) C1

Kenya Quality Model for Health - Hospitals

Download (6202)

View PDF (5490)

War Surgery. Vol.1
recommended

C. Giannou and M. Baldan International Committee of the Red Cross (2009) C1

Working with limited resources in armed conflict and other situations of violence. Vol.1

Download (483)

View PDF (627)

Social determinants of mental health

Fundação Calouste Gulbenkian World Health Organization WHO (2014) C_WHO

Good mental health is integral to human health and well being. A person’s mental health and many common mental disorders are shaped by various social, economic, and physical environments operating at different stages of life. Risk factors for many common mental disorders are heavily associated wit... more

Download (946)

View PDF (1574)

National Strategic Framework for the Elimination of Obstetrics Fistula in Nigeria 2011-2015

Federal Ministry of Health, Nigeria (2012) C1

Download (338)

View PDF (428)

Planetary Health 101 Information and Resources
recommended

Panorma Perspectives (2018) CC

The Panorama Perspectives: Conversations on Planetary Health report series aims to inspire new thinking, conversations, and engagement with planetary health and other integrated concepts. Collaboration and open knowledge sharing across sectors are necessary to solve the complex global health and dev... more

Download (295)

View PDF (322)

Identifying Early Adopters of COVID-19 Vaccines in Latin America

Arrieta, A.; A. García-Prado, J.P. Sarmiento, et al. Florida International University (2021) CC

COVID-19 vaccine hesitancy is currently one of the main obstacles to worldwide herd immunity and socioeconomic recovery. Because vaccine coverage can vary between and within countries, it is important to identify sources of variation so that policies can be tailored to different population groups. ... more

Download (435)

View PDF (527)

The Sustainable Development Goals Report 2022

United Nations (2022) C2

According to the Report, cascading and interlinked crises are putting the 2030 Agenda for Sustainable Development in grave danger, along with humanity’s very own survival. The Report highlights the severity and magnitude of the challenges before us. The confluence of crises, dominated by COVID-19,... more

Download (536)

View PDF (823)

The Core Elements of Human Antibiotic Stewardship Programs in Resource-Limited Settings: National and Hospital Levels
recommended

Centers for Disease Control and Prevention CDC (2018) C_CDC

Formularies are lists of antibiotics that are suggested for certain healthcare settings. In developing a recommended formulary, countries should consider the needs of patients and facilities where they receive care. For example, clinicians in rural or primary health centers may need wide access to f... more

Download (471)

View PDF (428)

Leveraging Vaccines to Reduce Antibiotic Use and Prevent Antimicrobial Resistance

World Health Organization WHO (2021) C_WHO

An Action Framework and annexe to Immunization Agenda 2030 (Draft version) 27 January 2021

Download (370)

View PDF (380)

Evaluation of COVID-19 vaccine effectiveness in a changing landscape of COVID-19 epidemiology and vaccination

World Health Organization WHO (2022) C_WHO

Interim Guidance October 2022. This addendum addresses some of the methodological aspects of VE evaluations that have been learned during the past year, as well as those that have become relevant in the current epidemiological setting of the COVID-19 pandemic. For some of the COVID-19 vaccine method... more

Download (330)

View PDF (592)

The Core Elements of Human Antibiotic Stewardship Programs in Resource-Limited Settings

Centers for Disease Control and Prevention CDC (2018) C_CDC

Antibiotic stewardship refers to coordinated efforts and activities that seek to measure and improve use of antibiotics. Implementation of ASPs has demonstrated positive public health and clinical impacts including reducing costs, lengths of hospital stays, and the burden of antibiotic resistance wh... more

War Surgery. Vol.1 recommended

Planetary Health 101 Information and Resources recommended

The Core Elements of Human Antibiotic Stewardship Programs in Resource-Limited Settings: National and Hospital Levels recommended

War Surgery. Vol.1
recommended

Planetary Health 101 Information and Resources
recommended

The Core Elements of Human Antibiotic Stewardship Programs in Resource-Limited Settings: National and Hospital Levels
recommended